ArticleClinical journal of gastroenterology2026
AFP-producing gastric cancer and hepatocellular carcinoma with discrepancies in AFP-L3 expression.
Article in Clinical journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alpha-fetoprotein (AFP) is widely used as a tumor biomarker in the diagnosis and surveillance of hepatocellular carcinoma (HCC). AFP is a glycoprotein bearing N-linked glycans, and can be classified into three glycoforms: AFP-L1, AFP-L2, and AFP-L3. AFP-L3, the α(1,6)-fucosylated isoform, is regarded as a highly specific biomarker for HCC and is often associated with aggressive tumor biology. In contrast, AFP-producing gastric carcinoma (AFPGC) is rare, and few studies have examined the relationship between AFP-L3 and AFPGC. Here, we present a case who developed AFP-positive HCC without AFP-L3 elevation, and subsequently AFPGC showing marked elevation of the AFP-L3 fraction. This demonstrates that AFP-L3 elevation is not entirely specific to HCC and may also be observed in AFPGC. Furthermore, this case highlights that fucosylation activity may differ among AFP-producing tumors arising in different organs within the same individual.
Indexed as
Identifiers
42113453What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.